Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (88)

« Back to Publications

n Insight into Cancer Cells and Disease Progression Through the Lens of Mathematical Modeling.

Michalakis P. et al, (2025), Curr Issues Mol Biol, 47

Synthesis, biological evaluation and mechanism study based on network pharmacology of amino acids esters of 20(S)-protopanaxadiol as novel anticancer agents.

Xie H. et al, (2025), Fitoterapia, 180

Biophysical interactions between components of the tumor microenvironment promote metastasis.

Vasilaki D. et al, (2021), Biophys Rev, 13, 339 - 357

The clinical landscape for AAV gene therapies.

Kuzmin DA. et al, (2021), Nat Rev Drug Discov, 20, 173 - 174

Evaluation of the Response of HOS and Saos-2 Osteosarcoma Cell Lines When Exposed to Different Sizes and Concentrations of Silver Nanoparticles.

Michalakis K. et al, (2021), Biomed Res Int, 2021

Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.

Gray V. et al, (2019), J Natl Cancer Inst, 111, 828 - 836

ssociation analyses identify 31 new risk loci for colorectal cancer susceptibility.

Law PJ. et al, (2019), Nat Commun, 10

Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.

Domingo E. et al, (2018), Lancet Gastroenterol Hepatol, 3, 635 - 643

The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial.

Huijbers A. et al, (2018), J Surg Oncol, 117, 1043 - 1048

Prognostic markers for colorectal cancer: estimating ploidy and stroma.

Danielsen HE. et al, (2018), Ann Oncol, 29, 616 - 623

Pharmacoproteomic characterisation of human colon and rectal cancer.

Frejno M. et al, (2017), Mol Syst Biol, 13

djuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557

ssociation of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts.

Schwantes-An T-H. et al, (2016), Behav Genet, 46, 151 - 169

Differential Efficacy of Nicotine Replacement Among Overweight and Obese Women Smokers.

Strong DR. et al, (2015), Nicotine Tob Res, 17, 855 - 861

The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver.

Geva R. et al, (2015), Cancer Invest, 33, 89 - 97

Load More

1
2
3
4
5
6